Bosutinib: a new, safer TKI for frontline CML

Bosutinib: a new, safer TKI for frontline CML

VJHemOnc

1 year
92 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The recent FDA approval of bosutinib makes it the fourth inhibitor for the frontline treatment of chronic myeloid leukemia (CML), as Michael Mauro, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, tells us in this interview. Dr Mauro explains how bosutinib has a unique safety profile that makes it more desirable than other inhibitors, such as imatinib, and emphasizes its use as a safe, effective inhibitor for CML patients (BFORE; NCT02130557). This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
Up Next Autoplay
Treating CML & Myelofibrosis Patients
Treating CML & Myelofibrosis Patients
Category: Chronic Myelogenous Leukemia
317 Views
imedex 10 months
Resistance/intolerance to second generation TKIs in CML: what to do next?
Resistance/intolerance to second generation TKIs in CML: what to do next?
Category: Chronic Myelogenous Leukemia
153 Views
VJHemOnc 1 year
Update on ENESTop: TFR in CML after discontinuing nilotinib
Update on ENESTop: TFR in CML after discontinuing nilotinib
Category: Chronic Myelogenous Leukemia
126 Views
VJHemOnc 1 year
Benefits of second generation TKIs for CML in the frontline
Benefits of second generation TKIs for CML in the frontline
Category: Chronic Myelogenous Leukemia
92 Views
VJHemOnc 1 year
Personalized therapy in leukemia: a case study
Personalized therapy in leukemia: a case study
Category: Chronic Myelogenous Leukemia
236 Views
VJHemOnc 1 year
New drugs for CML: are more to come?
New drugs for CML: are more to come?
Category: Chronic Myelogenous Leukemia
63 Views
VJHemOnc 1 year
Asciminib has the potential to succeed where other TKIs have failed in CML
Asciminib has the potential to succeed where other TKIs have failed in CML
Category: Chronic Myelogenous Leukemia
209 Views
VJHemOnc 1 year
DESTINY: achieving TFR by de-escalating therapy in CML
DESTINY: achieving TFR by de-escalating therapy in CML
Category: Chronic Myelogenous Leukemia
97 Views
VJHemOnc 1 year
Novel agents or imatinib for CML in the frontline setting?
Novel agents or imatinib for CML in the frontline setting?
Category: Chronic Myelogenous Leukemia
74 Views
VJHemOnc 1 year